Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid announced by Zelluna ASA on…
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8…
CRANSTON, R.I., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced…
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
December 07, 2025 16:00 ET | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…